PISCATAWAY, N.J. — Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launch of Voriconazole for Oral Suspension [vor-i-KON-a-zole].
Voriconazole for Oral Suspension is indicated for the treatment of adults and pediatric patients 2 years of age and older with various yeast and fungal infections affecting various parts of the body, and in some cases, in patients intolerant of, or refractory to, other therapy.
Voriconazole for Oral Suspension is available in 40 mg/mL.
For complete indications, click here
To learn more about this product, visit: Voriconazole for Oral Suspension
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
